Simvastatin, Sildenafil and Their Combination in Monocrotaline Induced Pulmonary Arterial Hypertension
Authors:
Open Access
- 1 January 2010
- journal article
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 40 (12) , 659-664
Abstract
Pulmonary arterial hypertension (PAH) is a life threatening disease characterized by progressive pulmonary arterial occlusion which may ultimately result in death. Currently, the available treatments are diverse, but no therapy alone can reverse the disease process although they may have some clinical benefits. This study was designed to investigate single and combination therapy of simvastatin and sildenafil, which have different mechanisms of action, in monocrotaline (MCT)-induced PAH. Rats were randomized to receive saline (control, n=8) or MCT treatment (n=32). MCT treated rats were randomized to vehicle, simvastatin (2 mg/kg/day), sildenafil (25 mg/kg/day) and a combination simvastatin and sildenafil (n=8, respectively). Three weeks later, hemodynamic study and histologic changes of pulmonary arterioles were measured. Proliferating cell nuclear antigen (PCNA) as well as Western blot for endothelial nitric oxide synthase (eNOS) were performed. Systolic right ventricular pressure was significantly decreased in monotherapy groups (simvastatin and sildenafil) and the combination group compared to MCT group (p<0.05). Right ventricular hypertrophy and medial wall thickness of pulmonary arterioles were significantly attenuated with sole and combination therapy (p<0.05). However, combination therapy did not confer additive benefits over monotherapy. Altered PCNA or eNOS in lung tissue was normalized by either monotherapy or combination therapy. The results suggest that either simvastatin or sildenafil has the therapeutic potential in MCT-induced PAH, although combination therapy of these two drugs has failed to show greater benefits in the study.Keywords
This publication has 30 references indexed in Scilit:
- Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in ratsPulmonary Pharmacology & Therapeutics, 2010
- Simvastatin and sildenafil combine to attenuate pulmonary hypertensionEuropean Respiratory Journal, 2009
- Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin studyAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2007
- Oral sildenafil prevents and reverses the development of pulmonary hypertension in monocrotaline-treated ratsInteractive CardioVascular and Thoracic Surgery, 2007
- Regression of chronic hypoxic pulmonary hypertension by simvastatinAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2007
- Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertensionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Simvastatin enhances bone morphogenetic protein receptor type II expressionBiochemical and Biophysical Research Communications, 2006
- Current treatment strategies for pulmonary arterial hypertensionJournal of Internal Medicine, 2005
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Clinical efficacy of sildenafil in primary pulmonary hypertensionJACC, 2004